Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report

Abstract

Background The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20mg rosuvastatin on biomarkers, including paraoxonase-1 (PON-1) and asymmetric dimethylarginine (ADMA), and on microvascular reactivity.

Method We enrolled 20 dyslipidemic patients with type 2 diabetes and 20 age- and body mass index (BMI)-matched healthy controls. Rosuvastatin (20mg/day) was given to the patient group for 12weeks. Biochemical parameters, including PON-1 and ADMA, were compared between the patient and control groups, and before and after rosuvastatin treatment in the patient group. Fasting and 2h postprandial levels of PON-1 and ADMA after mixed-meal challenge were also compared. Microvascular reactivity in a peripheral artery was examined using laser Doppler flowmetry.

Results The respective mean±standard deviation of age and BMI were 50.1±3.8year and 25.8±3.7kg/m2 in the patients and 50.2±3.2year and 25.4±3.4kg/m2 in the controls. The patient group had worse profiles of cardiometabolic biomarkers, including PON-1 and ADMA, than the controls. In the patients treated with 20mg rosuvastatin, low-density lipoprotein (LDL)-cholesterol decreased from 147.2±26.5 to 68.3±24.5mg/dL and high-density lipoprotein (HDL)-cholesterol increased from 42.4±5.2 to 44.7±6.2mg/dL (both P<0.05). Both fasting and 2h postprandial levels of PON-1 increased and those of ADMA decreased after treatment with rosuvastatin for 12weeks. The changes in postprandial levels of both biomarkers were greater than those after fasting. Microcirculation assessed as reactive hyperemia in the patients after an ischemic challenge increased significantly from 335.3±123.4 to 402.7±133.4% after rosuvastatin treatment. The postprandial changes in the biomarkers were significantly associated with improvement of microvascular reactivity.

Conclusions Rosuvastatin treatment for 12weeks improved microvascular reactivity with concomitant beneficial changes in the postprandial levels of PON-1 and ADMA. These results suggest that rosuvastatin improves the postprandial cardiometabolic milieu in type 2 diabetes.

Trial registration ClinicalTrials.gov: NCT02185963 (July 7, 2014)